|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
AN EVALUATIVE QUESTIONNAIRE STUDY OF FSIAD SYMPTOMATOLOGY, DISTRESS AND PREFERED MEDICATION USE IN WOMEN WITH FSIAD AND WOMEN WITH SELF-REPORTED SEXUAL INTEREST/AROUSAL PROBLEMS - FSIAD questionnaire study
A double-blind, randomized, placebo-controlled, proof of concept study to investigate the differences between the combined administration of 0.5 mg sublingual testosterone and 10 mg buspirone and 10 mg buspirone administration alone in women with hypoactive sexual desire disorder
A double-blind, randomized, placebo-controlled, proof of concept study to investigate the safety and efficacy of the combined administration of 0.5 mg sublingual testosterone and 10 mg tadalafil in women with hypoactive sexual desire disorder
100 Clinical Results associated with EB Beheer Almere BV
0 Patents (Medical) associated with EB Beheer Almere BV
100 Deals associated with EB Beheer Almere BV
100 Translational Medicine associated with EB Beheer Almere BV